|
Jul 2
|
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
|
|
Jun 2
|
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
|
|
May 27
|
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
|
|
Apr 30
|
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
|
|
Apr 28
|
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
|
|
Apr 28
|
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
|
|
Apr 25
|
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
|
|
Apr 24
|
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
|
|
Feb 11
|
BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|